The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Identification of an allosteric site on the E3 ligase adapter cereblon
Abstract
Cereblon (CRBN) is the target of thalidomide derivatives 1 that achieve therapeutic efficacy against some haematologic neoplasias 2-4 by recruiting neosubstrates for degradation 5-7 . Despite the intense investigation of orthosteric thalidomide derivatives, little is known about alternate binding sites on CRBN. Here we report an evolutionarily conserved cryptic allosteric binding site on CRBN. Small-molecule SB-405483 binds the allosteric site to cooperatively enhance the binding of orthosteric ligands and alter their neosubstrate degradation profiles. A survey of over 100 orthosteric ligands and their degradation targets reveals trends in the classes of compounds and neosubstrates in which degradation outcomes are enhanced or inhibited by SB-405483. Structural investigations provide a mechanistic basis for the effects of the allosteric ligand by shifting the conformational distribution of CRBN open to a novel CRBN int and increasing the CRBN closed state. The discovery of a cryptic allosteric binding site on CRBN that alters the functional effects of orthosteric ligands opens new directions with broad implications for improving the selectivity and efficacy of CRBN therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog
Russell, P., & Nurse, P. (1987) · Cell · doi:10.1016/0092-8674(87)90458-2 · Cited by 1,017
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 931
Cited by
Zhang, Y., Li, L., Xu, J., Che, C.-C., Jia, J., Lu, H., You, Q., & Xu, X. (2026) · Molecules · doi:10.3390/molecules31030459 · Cited by 5
“The understanding of mechanisms has expanded from initially shared motifs (such as G-loop) to a comprehensive model that includes molecular surface mimicry, allosteric regulation, and the analysis of complex ternary complex interfaces [128,132].”
Safety considerations for cereblon-recruiting targeted protein degraders
Garside, H., Aslamkhan, A. G., Daniels, D. L., Datta, K., Pedersen, M. E., Hukkanen, R. R., Jones, L. H., Ketter, N., Lahoti, T. S., Loberg, L. I., et al. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01426-2 · Cited by 11
“In addition, a recent publication identified a novel allosteric binding site on CRBN that might offer further opportunities to improve the selectivity of CRBN-TPDs 181 .”
An allosteric site on cereblon
Crunkhorn, S. (2026) · Nature Reviews Drug Discovery · doi:10.1038/d41573-026-00039-z
Nie, H., Wang, J., Xu, H., Zhou, Y.-J., Yin, G., Xu, X., Xu, G., Chen, B., Li, X., Hu, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.16.712139
Tong, J., Wang, P., Ma, S., Li, J., Zhan, Y., Liu, M., Jin, F., Qu, G., Zheng, C., Wang, X., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06132-1
“CRBN was famously identified as the primary target of the teratogenic effects of thalidomide and its immunomodulatory analogs, lenalido-mide and pomalidomide (collectively known as IMiDs) [8, 9].”
Metadata
- Authors
- Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., Curnutt, N. M., Kabir, F., Chan, K.-H., Queisser, M. A., Musetti, C., Dai, H., Lander, G. C., Benowitz, A. B., & Woo, C. M.
- Affiliations
- Harvard University (US)
- Scripps Research Institute (US)
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline Research & Development Limited (United Kingdom) (GB)
- Bristol-Myers Squibb (United States) (US)
- Broad Institute (US)
- Corresponding author
- Benowitz, Andrew B.
- Woo, Christina M.
- ORCID
- Venue
- Nature
- Published
- 2026-01-21
- Volume
- 651
- Issue
- 8105
- Pages
- 482-490
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W7125107855
- Cited by
- 14
- References
- 41
- Citations by year
- 2026: 14
- FWCI
- 28.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R21GM154216, R01GM143805)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- cereblon, allosteric site, E3 ubiquitin ligase, targeted protein degradation, thalidomide derivatives, protein conformational states
- MeSH terms
- Allosteric Regulation, Allosteric Site, Humans, Ligands, Models, Molecular, Peptide Hydrolases, Protein Binding, Thalidomide, Crystallography, X-Ray, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of an allosteric site on the E3 ligase adapter cereblon. https://app.cochat.ai/papers/10.1038/s41586-025-09994-w
- The paper
- Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., Curnutt, N. M., Kabir, F., Chan, K.-H., Queisser, M. A., Musetti, C., Dai, H., Lander, G. C., Benowitz, A. B., & Woo, C. M. (2026). Identification of an allosteric site on the E3 ligase adapter cereblon. Nature. https://doi.org/10.1038/s41586-025-09994-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.